Rabbit Recombinant Monoclonal IGF1 Receptor antibody. Carrier free. Suitable for IP, Flow Cyt, WB, ICC/IF and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Tested | Tested | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R. When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
CD221, Insulin-like growth factor 1 receptor, Insulin-like growth factor I receptor, IGF-I receptor, IGF1R
Rabbit Recombinant Monoclonal IGF1 Receptor antibody. Carrier free. Suitable for IP, Flow Cyt, WB, ICC/IF and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab267344 is the carrier-free version of Anti-IGF1 Receptor antibody [EPR23027-80] ab263907.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The IGF1 Receptor often referred to as IGF-1R is a transmembrane receptor protein composed of alpha and beta subunits. Studies indicate that the IGF1R protein is involved in mediating the effects of insulin-like growth factor 1 (IGF-1) and plays an important role in cellular signaling. It has a molecular weight of approximately 180 kDa and is widely expressed in various tissues with high concentrations in the liver muscle and brain. Being a tyrosine kinase receptor IGF1R plays an essential role in growth and metabolism.
IGF1R contributes to several cellular processes including cell proliferation differentiation and survival. This receptor forms a complex upon ligand binding and undergoes autophosphorylation to activate intracellular signaling cascades. IGF1R activation recruits and phosphorylates insulin receptor substrates enabling the downstream signaling pathways that promote cell growth and survival. Its function in cellular responses makes it a focal point in understanding cell biology.
IGF1R holds a central position in the PI3K/AKT and MAPK signaling cascades. These pathways play significant roles in cellular growth proliferation and survival. IGF1R phosphorylates various downstream effectors such as IRS-1 and Shc linking it to the activation of AKT and ERK respectively. Therefore it shares pathways with related proteins like the insulin receptor highlighting its importance in mediating similar biological responses.
IGF1R has been implicated in cancers and diabetes. Overexpression of IGF1R has been observed in various malignancies including breast cancer where it relates to resistance in treatment and poor prognosis with cell lines like MCF-7 often being studied in this context. Additionally disruptions in IGF1R signaling link to insulin resistance an important feature of type 2 diabetes. These connections make IGF1R a potential therapeutic target with IGF1R inhibitors currently under exploration to address these health challenges.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis MCF7 (human breast adenocarcinoma epithelial cell) cells labelling IGF1 Receptor with Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 at 1/500 dilution (Red) compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Black isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). A Goat anti rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) at 1/2000 dilution was used as the secondary antibody.
Gated on viable cells.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-IGF1 Receptor antibody [EPR23027-80] ab263907).
This data was developed using the same antibody clone in a different buffer formulation (Anti-IGF1 Receptor antibody [EPR23027-80] ab263907).
Lanes 1- 2: Merged signal (red and green). Green - Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 observed at 100 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) observed at 37 kDa.
Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 was shown to react with IGF1 Receptor in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human IGF1R (IGF1 Receptor) knockout HeLa cell line ab264801 (knockout cell lysate Human IGF1R (IGF1 Receptor) knockout HeLa cell lysate ab256951) was used. Wild-type HeLa and IGF1R knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-IGF1 Receptor antibody [EPR23027-80] (Anti-IGF1 Receptor antibody [EPR23027-80] ab263907) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: IGF1R knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human IGF1R (IGF1 Receptor) knockout HeLa cell line (Human IGF1R (IGF1 Receptor) knockout HeLa cell line ab264801)
Performed under reducing conditions.
Predicted band size: 154 kDa
Observed band size: 100 kDa
Immunofluorescent analysis of 100% Methanol-fixed MCF7 (human breast adenocarcinoma epithelial cell) cells labelling IGF1 Receptor with Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 at 1/100 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 AlexaFluor®488 Goat anti-Rabbit secondary antibody at 1/1000 dilution (Green). Confocal image showing membranous staining in MCF7 cell line. Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at1/200 dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 AlexaFluor®488 Goat anti-Rabbit secondary at 1/1000 dilution.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-IGF1 Receptor antibody [EPR23027-80] ab263907).
IGF1 Receptor was immunoprecipitated from 0.35 mg MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate with Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate 10ug
Lane 2: Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 IP in MCF7 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-IGF1 Receptor antibody [EPR23027-80] ab263907 in MCF7 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 min.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-IGF1 Receptor antibody [EPR23027-80] ab263907).
All lanes: Immunoprecipitation - Anti-IGF1 Receptor antibody [EPR23027-80] (Anti-IGF1 Receptor antibody [EPR23027-80] ab263907)
Predicted band size: 154 kDa
Observed band size: 130 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com